MedPath

Heron Therapeutics, Inc.

Heron Therapeutics, Inc. logo
πŸ‡ΊπŸ‡ΈUnited States
Ownership
Public
Established
1983-01-01
Employees
126
Market Cap
$292.7M
Website
http://www.herontx.com

A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE.

Phase 4
Completed
Conditions
Total Shoulder Arthroplasty
Multimodal Analgesia
Postoperative Pain
Interventions
First Posted Date
2023-10-31
Last Posted Date
2023-10-31
Lead Sponsor
Heron Therapeutics
Target Recruit Count
30
Registration Number
NCT06109415
Locations
πŸ‡ΊπŸ‡Έ

First Surgical Hospital, Bellaire, Texas, United States

πŸ‡ΊπŸ‡Έ

Legent Orthopedic Hospital, Carrollton, Texas, United States

πŸ‡ΊπŸ‡Έ

JBR Clinical Research, Salt Lake City, Utah, United States

and more 2 locations

A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE

Phase 4
Completed
Conditions
Analgesia
Interventions
First Posted Date
2023-10-31
Last Posted Date
2023-10-31
Lead Sponsor
Heron Therapeutics
Target Recruit Count
30
Registration Number
NCT06109428
Locations
πŸ‡ΊπŸ‡Έ

Endeavor Clinical Trials, LLC, San Antonio, Texas, United States

πŸ‡ΊπŸ‡Έ

First Surgical Hospital, Bellaire, Texas, United States

Safety Study of Repeat Doses of SUSTOL in Adults

Phase 4
Active, not recruiting
Conditions
Chemotherapy-Induced Nausea and Vomiting (CINV)
Interventions
First Posted Date
2022-06-28
Last Posted Date
2023-07-28
Lead Sponsor
Heron Therapeutics
Target Recruit Count
300
Registration Number
NCT05434663
Locations
πŸ‡ΊπŸ‡Έ

Gabrail Cancer Center Research, Canton, Ohio, United States

πŸ‡ΊπŸ‡Έ

Hattiesburg Clinic Hematology/Oncology, Hattiesburg, Mississippi, United States

A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE. Master Protocol HTX-011-401.

Phase 4
Active, not recruiting
Conditions
Analgesia
Interventions
First Posted Date
2021-11-05
Last Posted Date
2023-10-26
Lead Sponsor
Heron Therapeutics
Target Recruit Count
90
Registration Number
NCT05109312
Locations
πŸ‡ΊπŸ‡Έ

Endeavor Clinical Trials, LLC, San Antonio, Texas, United States

πŸ‡ΊπŸ‡Έ

First Surgical Hospital, Bellaire, Texas, United States

πŸ‡ΊπŸ‡Έ

Legent Orthopedic Hospital, Carrollton, Texas, United States

and more 4 locations

HTX-011 in Spinal Surgery

Phase 2
Completed
Conditions
Post-Operative Pain
Lumbar Laminectomy
Interventions
Drug: Bupivacaine HCI without epinephrine
Drug: HTX-011
Device: Luer Lock Applicator
First Posted Date
2021-06-02
Last Posted Date
2023-06-12
Lead Sponsor
Heron Therapeutics
Target Recruit Count
32
Registration Number
NCT04911062
Locations
πŸ‡ΊπŸ‡Έ

South Texas Spine & Surgical Center, San Antonio, Texas, United States

πŸ‡ΊπŸ‡Έ

M3 Emerging Medical Research, LLC, Durham, North Carolina, United States

πŸ‡ΊπŸ‡Έ

Austin Neurosurgeons, Austin, Texas, United States

and more 9 locations

Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)

Phase 2
Terminated
Conditions
COVID-19
Interventions
First Posted Date
2020-07-14
Last Posted Date
2022-08-30
Lead Sponsor
Heron Therapeutics
Target Recruit Count
27
Registration Number
NCT04470622
Locations
πŸ‡ΊπŸ‡Έ

Helen Keller Hospital, Sheffield, Alabama, United States

πŸ‡ΊπŸ‡Έ

University of California, Irvine Medical Center, Orange, California, United States

πŸ‡ΊπŸ‡Έ

Yale University School of Medicine, New Haven, Connecticut, United States

Dose-Escalation Study of HTX-034 Following Bunionectomy

Phase 1
Completed
Conditions
Bunions
Interventions
Drug: HTX-034
Drug: Bupivacaine HCl
Device: Luer lock applicator
First Posted Date
2020-05-21
Last Posted Date
2022-02-15
Lead Sponsor
Heron Therapeutics
Target Recruit Count
73
Registration Number
NCT04398329
Locations
πŸ‡ΊπŸ‡Έ

Endeavor Clinical Trials, LLC, San Antonio, Texas, United States

πŸ‡ΊπŸ‡Έ

Arizona Research Center, Phoenix, Arizona, United States

πŸ‡ΊπŸ‡Έ

JBR Clinical Research, Salt Lake City, Utah, United States

and more 1 locations

Extended Delivery of Bupivacaine Study in Herniorrhaphy

First Posted Date
2019-09-25
Last Posted Date
2019-09-26
Lead Sponsor
Heron Therapeutics
Target Recruit Count
32
Registration Number
NCT04102267
Locations
πŸ‡ΊπŸ‡Έ

Anaheim Clinical Trials, LLC, Anaheim, California, United States

Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) Regimen

Phase 3
Completed
Conditions
Analgesia
Interventions
Drug: HTX-011
Drug: Ibuprofen
Drug: Acetaminophen
Drug: +/- Bupivacaine HCl
Drug: Celecoxib
Device: Luer Lock Applicator
First Posted Date
2019-06-05
Last Posted Date
2023-08-31
Lead Sponsor
Heron Therapeutics
Target Recruit Count
116
Registration Number
NCT03974932
Locations
πŸ‡ΊπŸ‡Έ

Endeavor Clinical Trials, LLC., San Antonio, Texas, United States

πŸ‡ΊπŸ‡Έ

Helen Keller Hospital, Sheffield, Alabama, United States

πŸ‡ΊπŸ‡Έ

Phoenix Clinical Research, LLC, Tamarac, Florida, United States

and more 3 locations

HTX-011 Administration Study in Planned Caesarean Section Procedure

Phase 2
Completed
Conditions
Analgesia
Interventions
Drug: HTX-011
Device: Luer Lock Applicator
Drug: Ibuprofen
Drug: Acetaminophen
First Posted Date
2019-05-20
Last Posted Date
2022-03-14
Lead Sponsor
Heron Therapeutics
Target Recruit Count
25
Registration Number
NCT03955211
Locations
πŸ‡ΊπŸ‡Έ

Sharp Mary Birch Hospital for Women and Newborns, San Diego, California, United States

πŸ‡ΊπŸ‡Έ

UPMC Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States

πŸ‡ΊπŸ‡Έ

Helen Keller Hospital, Sheffield, Alabama, United States

and more 1 locations
Β© Copyright 2025. All Rights Reserved by MedPath